BioPharma Dive
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as best-in-disease and sent shares down more than 30%.
BioPharma Dive
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as best-in-disease and sent shares down more than 30%.
BioPharma Dive
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as best-in-disease and sent shares down more than 30%.